Assessment of topoisomerase II-alpha gene status by dual color chromogenic in situ hybridization in a set of Iraqi patients with invasive breast carcinoma | Zendy

RashaAbd Alraouf Neama | Zendy; ManalA Habib | Zendy; SahiraA Ali | Zendy; AliH Al-Khafaji | Zendy; Mohammed F. Alqanbar | Zendy

Open Access

Assessment of topoisomerase II-alpha gene status by dual color chromogenic in situ hybridization in a set of Iraqi patients with invasive breast carcinoma

Author(s) -

RashaAbd Alraouf Neama,

ManalA Habib,

SahiraA Ali,

AliH Al-Khafaji,

Mohammed F. Alqanbar

Publication year - 2017

Publication title -

indian journal of pathology and microbiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.217

H-Index - 31

eISSN - 0974-5130

pISSN - 0377-4929

DOI - 10.4103/ijpm.ijpm_62_16

Subject(s) - chromogenic , in situ , in situ hybridization , alpha (finance) , breast cancer , gene , medicine , biology , microbiology and biotechnology , chemistry , genetics , cancer , chromatography , gene expression , surgery , construct validity , organic chemistry , patient satisfaction

The human epidermal growth factor receptor 2(HER2) proto-oncogene is overexpressed or amplified in approximately 15%-25% of invasive breast cancers. Approximately 35% of HER2-amplified breast cancers have coamplification of the topoisomerase II-alpha (TOP2A) gene encoding an enzyme that is a major target of anthracyclines. Hence, the determination of genetic alteration (amplification or deletion) of both genes is considered as an important predictive factor that determines the response of breast cancer patients to treatment. The aims of this study are to determinate TOP2A status gene amplification in a set of Iraqi patients with breast cancer that have had an equivocal (2+) and positive HER2/neu by immunohistochemistry (IHC) and to compare the results with estrogen receptor (ER) and progesterone receptor (PR) and HER2/neu status.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research